Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Influence of Hydrogen Atoms on the Performance of Radial Distribution Function-Based Descriptors in the Chemoinformatic Studies of HIV-1 Protease Complexes with Inhibitors

Author(s): Jurica Novak*, Maria A. Grishina and Vladimir A. Potemkin

Volume 18, Issue 3, 2021

Published on: 02 January, 2020

Page: [414 - 422] Pages: 9

DOI: 10.2174/1570163817666200102130415

Price: $65

Abstract

Aims: The aim of this letter is to explore the influence of adding hydrogen atoms to the crystallographic structures of HIV-1 protease complexes with a series of inhibitors on the performance of radial distribution function based descriptors recently introduced in chemoinformatic studies.

Background: Quite recently the successful application of molecular descriptors based on a radial distribution function to correlate it with biologically interesting properties of a ligand – enzyme complex was demonstrated. Except its predictive power, the analysis of atoms with dominant contributions to the RDFs can be used to identify relevant atoms and interactions. Since original paper was published on dataset consisting of the X-ray structures of complexes without hydrogen atoms, we wonder weather addition of light atoms can provide us new piece of information.

Objective: The primarily objective is to create the model correlating the RDF based descriptors and physicochemical properties of the HIV-1 protease complexes with inhibitors with hydrogen atoms. Then, we will compare the performance of new model with previous one, where the hydrogen atoms were discarded. Information about interactions between the enzyme and the inhibitors will be extracted from the analysis of the RDF.

Methods: The radial distribution function descriptor weighted by the number of valence shell electrons has proven to be sensitive to the changes in the structure of the enzyme and enzyme-ligand complexes. For each structure in our data set, RDF will be calculated and using multiple linear regression method the mathematical model will be designed correlating RDF based descriptors and the physicochemical properties. Statistical analysis of the atom’s contribution to the total RDF will reveal relevant interactions.

Results: The applicability of RDF based descriptor for the correlation with pKi and EC50 values is demonstrated, while simple models containing only two or three parameters are able to explain 78 and 86 % of the variance, respectively. The models with explicitly included hydrogens are of comparable quality with the previous models without hydrogens. The analysis of the atom’s dominant contributions highlighted the importance of the hydroxyl groups of the inhibitor near the Asp25 and Asp25’ residues when it is bounded to the protease.

Conclusion: Models based on the RDF weighted by the number of valence shell electrons for correlating small number of molecular descriptors and physicocehmical properties for structures with and without hydrogens are of comparable quality and both can be used for identification of relevant functional groups and interactions.

Other: Our approach can be integrated to the next generation virtual screening methods, because is fast, reliable with high predictability potential.

Keywords: Radial distribution function, RDF, HIV protease, inhibitors, QSAR, drug design.

Graphical Abstract

[1]
Davies DR. The structure and function of the aspartic proteinases. Annu Rev Biophys Biophys Chem 1990; 19(1): 189-215.
[http://dx.doi.org/10.1146/annurev.bb.19.060190.001201] [PMID: 2194475]
[2]
Brik A, Wong CH. HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 2003; 1(1): 5-14.
[http://dx.doi.org/10.1039/b208248a] [PMID: 12929379]
[3]
Wang Y, Lv Z, Chu Y. HIV Protease Inhibitors: A Review of Molecular Selectivity and Toxicity. HIV/AIDS - Res. Palliat Care 2015; 7: 95.
[http://dx.doi.org/10.2147/HIV.S79956]
[4]
Navia MA, Fitzgerald PMD, McKeever BM, et al. Three-Dimensional Structure of Aspartyl Protease from Human Immunodeficiency Virus HIV-1. Nature 1989; 337(6208): 615-20.
[http://dx.doi.org/10.1038/337615a0]
[5]
Miller M, Schneider J, Sathyanarayana B K, et al. Structure of Complex of Synthetic HIV-1 Protease with a Substrate-Based Inhibitor at 2.3 Å Resolution. Science (80- ) 1989; 246(4934): 1149-52.
[http://dx.doi.org/10.1126/science.2686029]
[6]
Yang H, Nkeze J, Zhao RY. Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy. Cell Biosci 2012; 2(1): 32.
[http://dx.doi.org/10.1186/2045-3701-2-32] [PMID: 22971934]
[7]
Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J Mol Biol 2000; 301(5): 1207-20.
[http://dx.doi.org/10.1006/jmbi.2000.4018] [PMID: 10966816]
[8]
Ghosh AK, Osswald HL, Prato G. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. J Med Chem 2016; 59(11): 5172-208.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01697] [PMID: 26799988]
[9]
Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27(27): 249-84.
[http://dx.doi.org/10.1146/annurev.biophys.27.1.249] [PMID: 9646869]
[10]
Hyland LJ, Tomaszek TA Jr, Meek TD. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 1991; 30(34): 8454-63.
[http://dx.doi.org/10.1021/bi00098a024] [PMID: 1883831]
[11]
Rodriguez EJ, Angeles TS, Meek TD. Use of nitrogen-15 kinetic isotope effects to elucidate details of the chemical mechanism of human immunodeficiency virus 1 protease. Biochemistry 1993; 32(46): 12380-5.
[http://dx.doi.org/10.1021/bi00097a015] [PMID: 8241126]
[12]
Chen X, Tropsha A. Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state. J Med Chem 1995; 38(1): 42-8.
[http://dx.doi.org/10.1021/jm00001a009] [PMID: 7837238]
[13]
Wang YX, Freedberg DI, Yamazaki T, et al. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry 1996; 35(31): 9945-50.
[http://dx.doi.org/10.1021/bi961268z] [PMID: 8756455]
[14]
Nam KY, Chang BH, Han CK, Ahn SG, No KT. Investigation of the Protonated State of HIV-1 Protease Active Site. Bull Korean Chem Soc 2003; 24(6): 817-23.
[http://dx.doi.org/10.5012/bkcs.2003.24.6.817]
[15]
Chen J, Yang M, Hu G, Shi S, Yi C, Zhang Q. Insights into the functional role of protonation states in the HIV-1 protease-BEA369 complex: molecular dynamics simulations and free energy calculations. J Mol Model 2009; 15(10): 1245-52.
[http://dx.doi.org/10.1007/s00894-009-0452-y] [PMID: 19294437]
[16]
Torbeev VY, Kent SBH. Ionization state of the catalytic dyad Asp25/25¢ in the HIV-1 protease: NMR studies of site-specifically 13C labelled HIV-1 protease prepared by total chemical synthesis. Org Biomol Chem 2012; 10(30): 5887-91.
[http://dx.doi.org/10.1039/c2ob25569c] [PMID: 22659831]
[17]
Weber IT, Waltman MJ, Mustyakimov M, et al. Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design. J Med Chem 2013; 56(13): 5631-5.
[http://dx.doi.org/10.1021/jm400684f] [PMID: 23772563]
[18]
Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85(13): 4686-90.
[http://dx.doi.org/10.1073/pnas.85.13.4686] [PMID: 3290901]
[19]
Darke PL, Leu CT, Davis LJ, et al. Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. J Biol Chem 1989; 264(4): 2307-12.
[PMID: 2644259]
[20]
Sayer JM, Liu F, Ishima R, Weber IT, Louis JM. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem 2008; 283(19): 13459-70.
[http://dx.doi.org/10.1074/jbc.M708506200] [PMID: 18281688]
[21]
Seelmeier S, Schmidt H, Turk V, von der Helm K. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci USA 1988; 85(18): 6612-6.
[http://dx.doi.org/10.1073/pnas.85.18.6612] [PMID: 3045820]
[22]
Pillay D, Taylor S, Richman DD. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol 2000; 10(4): 231-53.
[http://dx.doi.org/10.1002/1099-1654(200007/08)10:4<231::AIDRMV290>3.0.CO;2-P] [PMID: 10891871]
[23]
Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374(6522): 569-71.
[http://dx.doi.org/10.1038/374569a0] [PMID: 7700387]
[24]
Maschera B, Darby G, Palu G, Wright L, Tisdale M. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease saquinavir complex. J Biol Chem 1996; 271(52): 33231-5.
[http://dx.doi.org/10.1074/jbc.271.52.33231] [PMID: 8969180]
[25]
Lockbaum GJ, Leidner F, Rusere LN, et al. Structural adaptation of darunavir analogues against primary mutations in HIV-1 protease. ACS Infect Dis 2019; 5(2): 316-25.
[http://dx.doi.org/10.1021/acsinfecdis.8b00336] [PMID: 30543749]
[26]
https://www.who.int/hiv/data/en/
[27]
Kramer-Hämmerle S, Rothenaigner I, Wolff H, Bell J E, Brack-Werner R. Cells of the Central Nervous System as Targets and Reservoirs of the Human Immunodeficiency Virus. Virus Res 2005; 111(2 SPEC. ISS): 194-213.
[http://dx.doi.org/10.1016/j.virusres.2005.04.009]
[28]
Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita 2011; 47(1): 44-8.
[http://dx.doi.org/10.4415/ANN_11_01_10] [PMID: 21430338]
[29]
Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384(9939): 258-71.
[http://dx.doi.org/10.1016/S0140-6736(14)60164-1] [PMID: 24907868]
[30]
Novak J, Grishina MA, Potemkin VA, Gasteiger J. The Performance of Radial Distribution Function Based Descriptors in the Chemoinformatic Studies of HIV-1 Protease. Future Med Chem 2020.
[http://dx.doi.org/10.4155/fmc-2019-0241]
[31]
Hemmer MC, Steinhauer V, Gasteiger J. Deriving the 3D Structure of Organic Molecules from Their Infrared Spectra. Vib Spectrosc 1999; 19(1): 151-64.
[http://dx.doi.org/10.1016/S0924-2031(99)00014-4]
[32]
Potemkin VA, Bartashevich EV, Belik AV. A new approach to predicting the thermodynamic parameters of substances from molecular characteristics. Russ J Phys Chem 1996; 70(3): 411-6.
[33]
Potemkin VA, Pogrebnoy AA, Grishina MA. Technique for energy decomposition in the study of “receptor-ligand” complexes. J Chem Inf Model 2009; 49(6): 1389-406.
[http://dx.doi.org/10.1021/ci800405n] [PMID: 19473000]
[34]
Potemkin V, Potemkin A, Grishina M. Internet Resources for Drug Discovery and Design. Curr Top Med Chem 2018; 18(22): 1955-75.
[http://dx.doi.org/10.2174/1568026619666181129142127] [PMID: 30499394]
[35]
González MP, Terán C, Fall Y, Teijeira M, Besada P. A radial distribution function approach to predict A(2B) agonist effect of adenosine analogues. Bioorg Med Chem 2005; 13(3): 601-8.
[http://dx.doi.org/10.1016/j.bmc.2004.10.063] [PMID: 15653328]
[36]
Morales AH, Cabrera Pérez MÁ, González MP. A radial-distribution-function approach for predicting rodent carcinogenicity. J Mol Model 2006; 12(6): 769-80.
[http://dx.doi.org/10.1007/s00894-005-0088-5] [PMID: 16421721]
[37]
Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000; 28(1): 235-42.
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID: 10592235]
[38]
http://www.rcsb.org/
[39]
HyperChem(TM) Professional 7.51, Hypercube, Inc. 1115 NW 4th Street, Gainesville, Florida 32601, USA.

Rights & Permissions Print Cite
Article Metrics
19
1
© 2024 Bentham Science Publishers | Privacy Policy